Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Healthcare Triangle (HCTI) Research & Development (2020 - 2025)

Healthcare Triangle filings provide 6 years of Research & Development readings, the most recent being $279000.0 for Q4 2025.

  • On a quarterly basis, Research & Development rose 448.75% to $279000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $537000.0, a 25.17% increase, with the full-year FY2025 number at $536000.0, up 24.94% from a year prior.
  • Research & Development reached $279000.0 in Q4 2025 per HCTI's latest filing, up from $59000.0 in the prior quarter.
  • The five-year high for Research & Development was $5.0 million in Q4 2022, with the low at -$80000.0 in Q4 2024.
  • A 5-year average of $757950.0 and a median of $243000.0 in 2024 define the central range for Research & Development.
  • Year-over-year, Research & Development tumbled 176.92% in 2024 and then surged 448.75% in 2025.
  • Year by year, Research & Development stood at $1.5 million in 2021, then skyrocketed by 234.35% to $5.0 million in 2022, then crashed by 97.9% to $104000.0 in 2023, then tumbled by 176.92% to -$80000.0 in 2024, then surged by 448.75% to $279000.0 in 2025.
  • Per Business Quant, the three most recent readings for HCTI's Research & Development are $279000.0 (Q4 2025), $59000.0 (Q3 2025), and $55000.0 (Q2 2025).